Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
2.870
+0.020 (0.70%)
At close: Jul 17, 2026, 4:00 PM EDT
2.931
+0.061 (2.11%)
After-hours: Jul 17, 2026, 7:59 PM EDT
Altimmune Employees
Altimmune had 57 employees as of December 31, 2025. The number of employees decreased by 2 or -3.39% compared to the previous year.
Employees
57
Change (1Y)
-2
Growth (1Y)
-3.39%
Revenue / Employee
$632
Profits / Employee
-$1,597,912
Market Cap
558.14M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57 | -2 | -3.39% |
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| Arvinas | 246 |
| 4D Molecular Therapeutics | 196 |
| Prime Medicine | 146 |
| Assembly Biosciences | 73 |
| AgomAb Therapeutics NV | 62 |
| Tectonic Therapeutic | 60 |
ALT News
- 25 days ago - Altimmune initiated with an Outperform at Leerink - TheFly
- 25 days ago - Altimmune initiated with an Outperform at Leerink - TheFly
- 5 weeks ago - Altimmune Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Altimmune Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide - TheFly
- 7 weeks ago - Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 - GlobeNewsWire
- 7 weeks ago - Altimmune to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 - GlobeNewsWire